Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Genetic Analysis AS's share price for the quarter that ended in Mar. 2026 was kr0.6. Genetic Analysis AS's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 69.09 Mil. Therefore, Genetic Analysis AS's market cap for the quarter that ended in Mar. 2026 was kr41.45 Mil.
Genetic Analysis AS's quarterly market cap
declined
from Sep. 2025 (kr61.83 Mil) to Dec. 2025 (kr48.36 Mil) and
declined
from Dec. 2025 (kr48.36 Mil) to Mar. 2026 (kr41.45 Mil).
Genetic Analysis AS's annual market cap
declined
from Dec. 2023 (kr32.47 Mil) to Dec. 2024 (kr25.19 Mil) but then
increased
from Dec. 2024 (kr25.19 Mil) to Dec. 2025 (kr48.36 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Genetic Analysis AS's Enterprise Value for Today is kr34.29 Mil.
Genetic Analysis AS (XSAT:GEAN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Genetic Analysis AS Market Cap Related Terms
Genetic Analysis AS Market Cap Historical Data
* Premium members only.
The historical data trend for Genetic Analysis AS's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:GEAN vs TMO, DHR, IDXX: Market Cap Comparison
For the Diagnostics & Research subindustry, Genetic Analysis AS's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Analysis AS Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Analysis AS's Market Cap distribution charts can be found below:
* The bar in red indicates where Genetic Analysis AS's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Genetic Analysis AS's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetic Analysis AS (XSAT:GEAN) has a Market Cap of kr45.60 Mil as of Jul. 19, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Genetic Analysis AS and its competitors. According to the industry distribution chart, Genetic Analysis AS ranks #191 out of 217 companies in the Medical Diagnostics & Research industry, placing it in the top 88%.
Is Genetic Analysis AS's Market Cap too high?
Genetic Analysis AS's current Market Cap is kr45.60 Mil. Based on the distribution chart, Genetic Analysis AS ranks #191 out of 217 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Genetic Analysis AS has a GF Score™ of 34/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genetic Analysis AS's Market Cap compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetic Analysis AS ranks #191 out of 217 companies for Market Cap. This places Genetic Analysis AS in the lower half of its industry. The industry median Market Cap is 57.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 57.95, based on 217 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Genetic Analysis AS and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 57.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetic Analysis AS's current Market Cap is kr45.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Analysis AS stock overvalued right now?
Based on GuruFocus' analysis, Genetic Analysis AS (XSAT:GEAN) is currently considered Modestly Overvalued. The stock's GF Value™ is kr0.54, compared to a current price of kr0.66 — trading 22.2% above its estimated fair value. The current Market Cap is kr45.60 Mil. Genetic Analysis AS's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Genetic Analysis AS (XSAT:GEAN), the current Market Cap is kr45.60 Mil as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genetic Analysis AS (XSAT:GEAN) Overvalued in 2026?
Based on GuruFocus' analysis, Genetic Analysis AS stock appears to be overvalued.
The current stock price of kr0.66 is trading 22.2% above its estimated GF Value™ of kr0.54.
GuruFocus considers Genetic Analysis AS to be Modestly Overvalued.
Key valuation signals for XSAT:GEAN:
Market Cap: kr45.60 Mil
GF Value™: kr0.54 vs. price of kr0.66 (22.2% above fair value)
No single metric tells the full story. See the XSAT:GEAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients. Geographically, it operates in the USA, Europe, and the Rest of the world. Geographically, the company sells products in the USA, Europe, and the rest of the world. The majority of its revenue is generated from the USA. The GA-map technology platform and product portfolio are currently used across three main market segments: Clinical diagnostics, research (academic and industry), and Consumer Health.
34GF Score
Get the complete analysis for XSAT:GEAN
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:GEAN has been successfully added to your 
